Proactiveinvestors recommends
Additional Information
Market: NASDAQ
Sector: Medical
EPIC: MEDW
Latest Price: 13.35  (0.53% Ascending)
52-week High: 14.75
52-week Low: 9.93
Market Cap: 107.93M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Mediware Info Systems
www.mediware.com

Mediware delivers interoperable best of breed software systems that improve efficiencies and address safety concerns to enable healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood centers; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; and business intelligence based performance management solutions for clinical, regulatory and financial aspects of the broader healthcare market.

Full Mediware Info Systems profile here
Pdf

Mediware second quarter EPS jumps 71% as acquisitions feed through to bottom line

8th Sep 2010, 4:45 pm
Mediware second quarter EPS jumps 71% as acquisitions feed through to bottom line

Mediware Information Systems  (NASDAQ: MEDW) reported at 25% surge in fourth quarter (3 months to June 30) revenues to US$13.3 million due largely to several  recent acquisitions. Fourth-quarter earnings per diluted share rose to 12 cents, a 71% increase over the 7 cents per diluted share reported in the same period in fiscal 2009.


Mediware delivers interoperable software systems that improve efficiencies and address safety concerns to enable healthcare organizations to improve care processes while cutting costs.


"Our medication management products, along with our acquisitions, were the primary drivers behind our revenue growth," said Thomas Mann, Mediware's president and chief executive officer. "While delivering strong operating results, we also invested heavily in future growth by increasing our R&D spend by nearly a million dollars."


For the full year Mediware chalked up revenues of US$47.6 million, a 17% increase, while full year earnings per diluted share were 41 cents, up more than 100% on the previous year.


"Our medication management products, along with our acquisitions, were the primary drivers behind our revenue growth," said Thomas Mann, Mediware's president and chief executive officer. "While delivering strong operating results, we also invested heavily in future growth by increasing our R&D spend by nearly a million dollars."


During the year, Mediware snapped up Healthcare Automation, Advantage Reimbursement and Knowledge-Forge.


The company also improved its cash pile by $2.5 million to $23.3 million during the year.


Core Mediware solutions include blood management technologies for hospitals and blood centers; medication management solutions for hospitals, behavioural health facilities, infusion and specialty pharmacy providers; and business intelligence based performance management solutions.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.